Literature DB >> 12629348

Disseminated tumor cells in bone marrow of patients with transitional cell carcinoma: immunocytochemical detection and correlation with established prognostic indicators.

Thomas Hofmann1, Rainer Riesenberg, Alexander Buchner, Wolfgang Zimmermann, Alfons Hofstetter, Ralph Oberneder.   

Abstract

PURPOSE: Previous investigations have demonstrated the prognostic value of disseminated cytokeratin positive cells in bone marrow of patients with breast, gastric, colon and prostate cancer. We evaluated the potential of an immunocytochemical assay, using a monoclonal antibody against cytokeratin 18 (CK 18), for the detection of disseminated tumor cells in bone marrow aspirates of patients with transitional cell carcinoma.
MATERIALS AND METHODS: Bone marrow aspiration was performed preoperatively on 128 patients with transitional cell carcinoma of various stages and on 27 controls with nonmalignant disease. Cytospin preparations of mononuclear bone marrow cells were incubated with a monoclonal anti-CK 18 antibody and stained using the alkaline phosphatase anti-alkaline phosphatase technique.
RESULTS: Of the patients with transitional cell carcinoma 29.7% and none of the controls had a CK 18 positive bone marrow result. A significant correlation between the incidence of CK 18 positive cells in bone marrow and invasive transitional cell carcinoma (p <0.01), lymph node involvement (p <0.01), medium/high grade transitional cell carcinoma (p <0.01) and tumor progression in recurrent transitional cell carcinoma (p <0.05) was demonstrated. Furthermore, the mean number of CK 18 positive cells in bone marrow aspirates of patients with stage M+ and/or N+ disease was nearly 3 times as high as that of patients without clinically evident metastatic disease (10.4 versus 3.8 CK 18 positive cells per patient).
CONCLUSIONS: A significant correlation between the incidence of CK 18 positive bone marrow results in patients with transitional cell carcinoma and established risk factors could be demonstrated in our study. Further prospective followup studies should be performed to determine the prognostic value of these findings.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12629348     DOI: 10.1097/01.ju.0000054917.31718.cd

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  Recent advances in the field of urology.

Authors:  Chester J Koh; Anthony Atala
Journal:  Curr Urol Rep       Date:  2006-01       Impact factor: 3.092

Review 2.  [Prostate and bladder cancer: detection of disseminated tumor cells in bone marrow].

Authors:  R Nawroth; D Weckermann; M Retz
Journal:  Urologe A       Date:  2014-04       Impact factor: 0.639

3.  Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.

Authors:  Ilona N Holcomb; Douglas I Grove; Martin Kinnunen; Cynthia L Friedman; Ian S Gallaher; Todd M Morgan; Cassandra L Sather; Jeffrey J Delrow; Peter S Nelson; Paul H Lange; William J Ellis; Lawrence D True; Janet M Young; Li Hsu; Barbara J Trask; Robert L Vessella
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

4.  Tumor cell invasion in blood vessels assessed by immunohistochemistry is related to decreased survival in patients with bladder cancer treated with radical cystectomy.

Authors:  Birgitte Carlsen; Tor Audun Klingen; Bettina Kulle Andreassen; Erik Skaaheim Haug
Journal:  Diagn Pathol       Date:  2021-11-22       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.